Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Samuel Moser"'
Autor:
Christian Klein, Inja Waldhauer, Valeria G. Nicolini, Anne Freimoser-Grundschober, Tapan Nayak, Danielle J. Vugts, Claire Dunn, Marije Bolijn, Jörg Benz, Martine Stihle, Sabine Lang, Michaele Roemmele, Thomas Hofer, Erwin van Puijenbroek, David Wittig, Samuel Moser, Oliver Ast, Peter Brünker, Ingo H. Gorr, Sebastian Neumann, Maria Cristina de Vera Mudry, Heather Hinton, Flavio Crameri, Jose Saro, Stefan Evers, Christian Gerdes, Marina Bacac, Guus van Dongen, Ekkehard Moessner, Pablo Umaña
Publikováno v:
OncoImmunology, Vol 6, Iss 3 (2017)
We developed cergutuzumab amunaleukin (CEA-IL2v, RG7813), a novel monomeric CEA-targeted immunocytokine, that comprises a single IL-2 variant (IL2v) moiety with abolished CD25 binding, fused to the C-terminus of a high affinity, bivalent carcinoembry
Externí odkaz:
https://doaj.org/article/a319ded80cfa47ca96224b37437a82ff
Publikováno v:
mAbs
Novel biotherapeutic glycoproteins, like recombinant monoclonal antibodies (mAbs) are widely used for the treatment of numerous diseases. The N-glycans attached to the constant region of an antibody have been demonstrated to be crucial for the biolog
Publikováno v:
2017 IEEE 6th International Conference on Renewable Energy Research and Applications (ICRERA).
IEEE Std. 1584 specifies that capacitors must be part of the arc-flash study. The software tools generally adopted for analytical studies are not suitable for the calculation of the arc-fault incident energy in the presence of capacitor banks. The re
Autor:
Ramona Murr, Elisabetta Ada Cavalcanti-Adam, Juana Merino, Reto Gianotti, Aintzane Zabaleta, Marina Bacac, Anthony D. Ho, Martina Emde, Jose Antonio Delgado, Samuel Moser, Felipe Prosper, Lydia Jasmin Harnisch, Anna Luise Grab, Jens Hillengass, Melanie Latzko, Klaus Strein, Ralf Hosse, Tanja Fauti, Jesús F. San Miguel, Remo Lüoend, Brigitte Neuber, Bruno Paiva, Pablo Umana, Minh Diem Vu, Christian Klein, Camille Delon, Anja Seckinger, Susanne Lipp, Michael Hundemer, Laura Moreno, Dirk Hose
Publikováno v:
Cancer Cell
Dadun. Depósito Académico Digital de la Universidad de Navarra
instname
Dadun. Depósito Académico Digital de la Universidad de Navarra
instname
We identified B cell maturation antigen (BCMA) as a potential therapeutic target in 778 newly diagnosed and relapsed myeloma patients. We constructed an IgG-based BCMA-T cell bispecific antibody (EM801) and showed that it increased CD3+ T cell/myelom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f3e8fb7b6e31ecaf1ebc31b68dfbe19
https://biblio.vub.ac.be/vubir/target-expression-generation-preclinical-activity-and-pharmacokinetics-of-the-bcmat-cell-bispecific-antibody-em801-for-multiple-myeloma-treatment(3de0c7eb-7a6c-49c6-ab48-956cf6c1a52a).html
https://biblio.vub.ac.be/vubir/target-expression-generation-preclinical-activity-and-pharmacokinetics-of-the-bcmat-cell-bispecific-antibody-em801-for-multiple-myeloma-treatment(3de0c7eb-7a6c-49c6-ab48-956cf6c1a52a).html
Autor:
Sabine Lang, Guus A.M.S. van Dongen, Oliver Ast, Tapan K. Nayak, Heather Hinton, Erwin van Puijenbroek, Hofer Thomas U, Michaele Roemmele, Peter Brünker, Ingo H. Gorr, Samuel Moser, Marije Bolijn, Sebastian Neumann, Jörg Benz, Flavio Crameri, Ekkehard Moessner, Martine Stihle, Danielle J. Vugts, Maria Cristina De Vera Mudry, Marina Bacac, David Wittig, Pablo Umana, Inja Waldhauer, Jose Saro, Anne Freimoser-Grundschober, Christian Klein, Claire Dunn, Stefan Evers, Nicolini Valeria G, Christian Gerdes
Publikováno v:
OncoImmunology, 6(3):e1277306. Landes Bioscience
OncoImmunology, Vol 6, Iss 3 (2017)
Klein, C, Waldhauer, I, Nicolini, V G, Freimoser-Grundschober, A, Nayak, T, Vugts, D J, Dunn, C, Bolijn, M, Benz, J, Stihle, M, Lang, S, Roemmele, M, Hofer, T, van Puijenbroek, E, Wittig, D, Moser, S, Ast, O, Brünker, P, Gorr, I H, Neumann, S, de Vera Mudry, M C, Hinton, H, Crameri, F, Saro, J, Evers, S, Gerdes, C, Bacac, M, van Dongen, G, Moessner, E & Umaña, P 2017, ' Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy : Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines ', OncoImmunology, vol. 6, no. 3, e1277306 . https://doi.org/10.1080/2162402X.2016.1277306
Oncoimmunology
OncoImmunology, Vol 6, Iss 3 (2017)
Klein, C, Waldhauer, I, Nicolini, V G, Freimoser-Grundschober, A, Nayak, T, Vugts, D J, Dunn, C, Bolijn, M, Benz, J, Stihle, M, Lang, S, Roemmele, M, Hofer, T, van Puijenbroek, E, Wittig, D, Moser, S, Ast, O, Brünker, P, Gorr, I H, Neumann, S, de Vera Mudry, M C, Hinton, H, Crameri, F, Saro, J, Evers, S, Gerdes, C, Bacac, M, van Dongen, G, Moessner, E & Umaña, P 2017, ' Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy : Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines ', OncoImmunology, vol. 6, no. 3, e1277306 . https://doi.org/10.1080/2162402X.2016.1277306
Oncoimmunology
We developed cergutuzumab amunaleukin (CEA-IL2v, RG7813), a novel monomeric CEA-targeted immunocytokine, that comprises a single IL-2 variant (IL2v) moiety with abolished CD25 binding, fused to the C-terminus of a high affinity, bivalent carcinoembry
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f94cba31a29a6556c5c8828f4eec574f
https://research.vumc.nl/en/publications/c3698f17-7a30-4c34-908d-56ad5f91e5cf
https://research.vumc.nl/en/publications/c3698f17-7a30-4c34-908d-56ad5f91e5cf
Autor:
Ekkehard Moessner, Pablo Umana, Tilman Schlothauer, Hubert Kettenberger, Lei Shi, Tina Weinzierl, Peng Wang, Natascha Rieder, Halina Trochanowska, Ralf Hosse, Carola Ries, Cuiying Shao, Katharina Wartha, Thomas Friess, Juergen Michael Schanzer, Samuel Moser, Rebecca Croasdale, Marina Bacac, Christian Klein
Publikováno v:
mAbs
The epidermal growth factor receptor (EGFR) and the insulin-like growth factor-1 receptor (IGF-1R) play critical roles in tumor growth, providing a strong rationale for the combined inhibition of IGF-1R and EGFR signaling in cancer therapy. We descri
Publikováno v:
Agricultural Water Management. 81:41-58
Water and nitrogen (N) are the most limiting factors for grain yield of maize ( Zea mays L.) in the tropics. In Thailand, the risk of water shortage is highest during the vegetative stages of maize development. A 3-year study with two water regimes (
Publikováno v:
Biotechnology and Bioengineering. 93:851-861
The effector functions elicited by IgG antibodies strongly depend on the carbohydrate moiety linked to the Fc region of the protein. Therefore several approaches have been developed to rationally manipulate these glycans and improve the biological fu
Autor:
Linda Fahrni, Sylvia Herter, Oliver Ast, Ralf Hosse, Sabine Lang, Pablo Umana, Sherri Dudal, Tanja Fauti, Wolfgang Schäfer, Christian Klein, Ekkehard Mössner, Inja Waldhauer, Christiane Neumann, Samuel Moser, Peter Brünker, Sara Colombetti, Erwin van Puijenbroek, Johannes Sam, Tina Weinzierl, Jörg T. Regula, Anne Freimoser-Grundschober, Marina Bacac
Publikováno v:
Cancer Research. 77:3629-3629
T cell bispecific antibodies that recruit and engage T cells for tumor cell killing through binding to the T cell receptor (TCR) upon binding to a tumor antigen (TA) and subsequent crosslinking have attracted broad interest. Here, we describe a novel
Autor:
Katharina Wartha, Ulrich Brinkmann, Klaus-Peter Künkele, Harald Duerr, Wilma Lau, Pablo Umana, Christian Klein, Werner Scheuer, Carola Ries, Stefan Ries, Sandra Pompiati, Jan Olaf Stracke, Juergen Michael Schanzer, Jan Pollman, Samuel Moser, Rebecca Croasdale
In the present study, we have developed a novel one-arm single chain Fab heterodimeric bispecific IgG (OAscFab-IgG) antibody format targeting the insulin-like growth factor receptor type I (IGF-1R) and the epidermal growth factor receptor (EGFR) with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52a1a87e51381876f543913c3a25ce97
https://europepmc.org/articles/PMC4081915/
https://europepmc.org/articles/PMC4081915/